ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet.

Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch.  This translates into a mean 4.5 mmHg reduction, which results significative (p=0.02).

In addition, there was significant reduction to 24 ambulatory systolic blood pressure, as well as office blood pressure. 

Even though all patients included in the study had been treated with a combination of at least 3 drugs (one of them a diuretic) their blood pressure readings still remained over 150 mmHg.

After the disappointing outcomes of SYMPLCITY HTN-3, the technique was considerably improved and there are now studies with positive results. The device used in RADIANCE-HTN TRIO is assisted by ultrasound to apply 2 or 3 7-second circumferential applications to the renal artery. 

All eligible patients for this study were changed to a fix drug scheme including a calcium beta blocker, an angiotensin inhibitor, and a thiazide diuretic. If after 4 weeks patients continued to present daily hypertension readings over 135/85 mmHg, they were randomized to ultrasound renal denervation vs. the sham procedure. 


Read also: ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI.


989 patients were enrolled, and 69 were finally randomized to denervation and 67 to the sham procedure. This was basically because after 4 weeks researchers were able to reach blood pressure targets.

At 2 months, the active Branch saw a significant reduction of all hypertension variables, including the primary end point of ambulatory daytime blood pressure. 

The only adverse event was a femoral access site pseudoaneurysm in the denervation Branch. 

Original Title: Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomized, multicenter, single-blind, sham-controlled trial.

Reference: Azizi M et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet 2021; Epub ahead of print. DOI:https://doi.org/10.1016/S0140-6736(21)00788-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is abdominal aortic aneurysm screening cost-effective in women?

Although ultrasound screening for abdominal aortic aneurysm (AAA) is a well-established strategy in men over 65 years of age, its value in women remains...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...